1
|
Zeng Z, Zheng W, Hou P. The role of drug-metabolizing enzymes in synthetic lethality of cancer. Pharmacol Ther 2022; 240:108219. [PMID: 35636517 DOI: 10.1016/j.pharmthera.2022.108219] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 05/23/2022] [Accepted: 05/24/2022] [Indexed: 12/14/2022]
Abstract
Drug-metabolizing enzymes (DMEs) have shown increasing importance in anticancer therapy. It is not only due to their effect on activation or deactivation of anticancer drugs, but also because of their extensive connections with pathological and biochemistry changes during tumorigenesis. Meanwhile, it has become more accessible to discovery anticancer drugs that selectively targeted cancer cells with the development of synthetic lethal screen technology. Synthetic lethal strategy makes use of unique genetic markers that different cancer cells from normal tissues to discovery anticancer agents. Dysregulation of DMEs has been found in various cancers, making them promising candidates for synthetic lethal strategy. In this review, we will systematically discuss about the role of DMEs in tumor progression, the application of synthetic lethality strategy in drug discovery, and a link between DMEs and synthetic lethal of cancer.
Collapse
Affiliation(s)
- Zekun Zeng
- Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China
| | - Wenfang Zheng
- Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China
| | - Peng Hou
- Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, PR China.
| |
Collapse
|
2
|
Thapa D, Meng P, Bedolla RG, Reddick RL, Kumar AP, Ghosh R. NQO1 suppresses NF-κB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis. Cancer Res 2014; 74:5644-55. [PMID: 25125658 DOI: 10.1158/0008-5472.can-14-0562] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
UNLABELLED NADPH reductase NAD(P)H quinone oxidoreductase 1 (NQO1) is needed to maintain a cellular pool of antioxidants, and this enzyme may contribute to tumorigenesis on the basis of studies in NQO1-deficient mice. In this work, we sought deeper insights into how NQO1 contributes to prostate carcinogenesis, a setting in which oxidative stress and inflammation are established contributors to disease development and progression. In the TRAMP mouse model of prostate cancer, NQO1 was highly expressed in tumor cells. NQO1 silencing in prostate cancer cells increased levels of nuclear IKKα and NF-κB while decreasing the levels of p53, leading to interactions between NF-κB and p300 that reinforce survival signaling. Gene expression analysis revealed upregulation of a set of immune-associated transcripts associated with inflammation and tumorigenesis in cells in which NQO1 was attenuated, with IL8 confirmed functionally in cell culture as one key NQO1-supported cytokine. Notably, NQO1-silenced prostate cancer cells were more resistant to androgen deprivation. Furthermore, NQO1 inhibition increased migration, including under conditions of androgen deprivation. These results reveal a molecular link between NQO1 expression and proinflammatory cytokine signaling in prostate cancer. Furthermore, our results suggest that altering redox homeostasis through NQO1 inhibition might promote androgen-independent cell survival via opposing effects on NF-κB and p53 function.
Collapse
Affiliation(s)
- Dinesh Thapa
- Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas
| | - Peng Meng
- Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas
| | - Roble G Bedolla
- Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas
| | - Robert L Reddick
- Department of Pathology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas. Cancer Therapy and Research Center, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas
| | - Addanki P Kumar
- Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas. Cancer Therapy and Research Center, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas. Department of Molecular Medicine, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas. South Texas Veterans Health Care System, San Antonio, Texas
| | - Rita Ghosh
- Department of Urology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas. Cancer Therapy and Research Center, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas. Department of Pharmacology, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas. Department of Molecular Medicine, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio Texas.
| |
Collapse
|